It’s been two years since President Obama signed the Jumpstart Our Business Startups (JOBS) Act into law and revamped the rules that govern private companies trying to raise money from all types of investors. The biotech crowd, usually hard pressed to find good things to say about federal regulation, couldn’t be more pleased with the … Continue reading “At Two-Year Mark, JOBS Act Is Regulation Even A Biotech Can Love”
Author: Alex Lash
I've spent nearly all my working life as a journalist. I covered the rise and fall of the dot-com era in the second half of the 1990s, then switched to life sciences in the new millennium. I've written about the strategy, financing and scientific breakthroughs of biotech for The Deal, Elsevier's Start-Up, In Vivo and The Pink Sheet, and Xconomy.
Seeking Tau: BMS Buys iPierian and Brain-Disease Program for $175M
Born five years ago from the merger of two cutting-edge stem cell companies, iPierian has agreed to an acquisition. Bristol-Myers Squibb is buying the South San Francisco-based biotech firm for $175 million upfront, with potentially $550 million more based on the progress of iPierian’s pipeline of antibodies to treat tau-mediated neurodegenerative disease. Details of those … Continue reading “Seeking Tau: BMS Buys iPierian and Brain-Disease Program for $175M”
Indi Reels In $47M To Push Launch Of Lung Cancer Diagnostic
Lung cancer diagnostic company Integrated Diagnostics launched its first product last fall, and now it has plenty of cash to go out and sell it. The firm, which grew out of Seattle’s Institute for Systems Biology and the California Institute of Technology, said Tuesday it has raised $47 million in equity and debt. The cash … Continue reading “Indi Reels In $47M To Push Launch Of Lung Cancer Diagnostic”
Amid Court Fight and Trial Pauses, Juno Closes First Round at $176M
Supercharged Seattle startup Juno Therapeutics said Thursday it has topped off its first round of venture funding, totaling $176 million in one of the largest cash infusions a private biotech has ever received. It’ll need every penny, and more. Not only is Juno trying to launch an ambitious set of clinical trials in the burgeoning … Continue reading “Amid Court Fight and Trial Pauses, Juno Closes First Round at $176M”